ACEA 1011

a glycine site NMDA receptor antagonist; produces analgesia during the late phase of subcutaneous formalin injection in mice

Also Known As:

5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione; ACEA-1011

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

1.	Pain (Aches) 12/01/1995 - "5-Chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione (ACEA-1011) has analgesic properties in animal models of tonic pain. " 07/02/1993 - "Similarly, blockade of the NMDA receptor allosteric site by the novel glycine site antagonist, ACEA-1011, also reduced the pain response in the late phase. " 07/02/1993 - "NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin."
2.	Myoclonus (Nocturnal Myoclonus) 03/06/1995 - "The novel strychnine-insensitive glycine site antagonists ACEA-1011 (5-chloro-7-trifluoromethyl-1,2,3,4-tetrahydroquinoxaline-2,3,-dio ne) and ACEA-1021 (5-nitro-6,7-dichloro-quinoxalinedione) significantly attenuated the myoclonus in cardiac-arrested rats. "
3.	Ataxia (Dyssynergia) 03/05/1999 - "The excitatory amino acid receptor antagonists, dizocilpine [(+)-MK-801; (5R,1OS)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten+ ++-5,10-imine], (+/-)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP), LY 326325 [(-)-(3S,4aR,6R,8R)-6-[2-(1(2)H-tetrazol-5-yl)-ethyl]-dec ahydroisoquinaline-3-carboxylic acid], LY 300164 [7,8-methylenedioxy-1-(4-aminophenyl)-4-methyl-3-acetyl-4,5-dihydro-2,3- benzodiazepine], and ACEA 1011 (5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione) produced dose-dependent myorelaxation/ataxia in mice as determined using the horizontal wire assay. "

1.	Dizocilpine Maleate (Dizocilpine)
2.	Glycine (Aminoacetic Acid)
3.	Glutamate Receptors (Glutamate Receptor)
4.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
5.	Strychnine
6.	Imines
7.	Formaldehyde (Formol)
8.	Benzodiazepines
9.	Analgesics (Analgesic Drugs)
10.	Acids